Diabetes mellitus (DM), a chronic metabolic disease characterised by elevated levels of
blood glucose, is among the most common chronic diseases. The incidence and prevalence …

Chronic heart failure is the end stage of cardiac diseases. With a high prevalence and a high
mortality rate worldwide, chronic heart failure is one of the heaviest health-related burdens …

Background: Sodium-glucose cotransporter-2 inhibitors are foundational therapy in patients
with heart failure with reduced ejection fraction (HFrEF), but underlying mechanisms of …

Background Heart failure with preserved ejection fraction (HFpEF) and HF with reduced
ejection fraction (HFrEF) are associated with metabolic derangements, which may have …

Heart failure with preserved ejection fraction (HFpEF) accounts for almost half of all heart
failure (HF) cases worldwide. Unfortunately, its incidence is expected to continue to rise, and …

Heart failure with preserved ejection fraction (HFpEF) is a heterogeneous disorder
developing from multiple aetiologies with overlapping pathophysiological mechanisms …

Because of remarkable surgical and medical advances over the past several decades, there
are growing numbers of infants and children living with single ventricle congenital heart …

Esophageal squamous cell carcinoma (ESCC) is one of the most common aggressive
malignancies worldwide, particularly in northern China. The absence of specific early …

Mitochondrial abnormalities have long been described in the setting of cardiomyopathies
and heart failure (HF), yet the mechanisms of mitochondrial dysfunction in cardiac …

Background In murine heart failure models and in humans with diabetic‐related heart
hypertrophy, inhibition of phosphodiesterase 5 (PDE 5) by sildenafil improves cardiac …